PR: HEPHAISTOS secures €10.3 M to reach the clinical stage HEPHAISTOS-Pharma welcomes Elaia to complete its Seed Round, securing a total of €10.3 million from investors and non-dilutive financing. €4.5M seed round led by Elaia with xista sciences ventures, Fondation Fournier-Majoie, Noshaq, Angels Santé and Femmes Business Angels.

公关：HEPHAISTOS获得1030万欧元进入临床阶段HEPHAISTOS Pharma欢迎Elaia完成其种子回合，从投资者和非稀释性融资中获得总计1030万欧元。Elaia与xista sciences ventures、Fournation Fournier Majoie、Noshaq、Angels Santé和Femmes Business Angels共同发起了450万欧元的种子回合。

€5.8M non-dilutive funding from the EIC accelerator, Bpifrance i-Nov, and France 2030 clinical grant. ONCO-Boost is a first-in-class immunostimulant targeting innate immune response to treat cancers non-responding to current regimens, including immunotherapies. France, May 16th, 2024. HEPHAISTOS-Pharma, a biotechnology company developing next generation immunotherapies against cancer targeting innate immunity to increase the cure rate of patients, has completed its €4.5 million seed round to finance industrialization and advance its lead candidate ONCO-Boost towards the clinic.

来自EIC加速器，Bpifrance i-Nov和法国2030临床赠款的580万欧元非稀释资金。ONCO Boost是针对先天免疫反应的一流免疫刺激剂，用于治疗对当前方案（包括免疫疗法）无反应的癌症。法国，2024年5月16日。HEPHAISTOS Pharma是一家开发针对先天免疫的下一代癌症免疫疗法以提高患者治愈率的生物技术公司，已完成450万欧元的种子回合，为工业化提供资金，并将其主要候选ONCO推进临床。

Elaia leads a consortium previously initiated by xista science ventures, the Fondation Fournier-Majoie and Noshaq. Florian DENIS, Investment Director at Elaia, stated: “Elaia is very proud to join and strengthen the syndication. HEPHAISTOS’ core technology based on immunostimulants has the potential to turn cold tumors into hot tumors in hard-to-treat cancers.

Elaia领导着一个由xista science ventures、Fournier Majoie基金会和Noshaq发起的财团。Elaia投资总监弗洛里安·丹尼斯（FlorianDenis）表示：“Elaia非常自豪能加入并加强这一财团。HEPHAISTOS基于免疫刺激剂的核心技术有可能将难治性癌症的冷肿瘤转变为热肿瘤。

Frédéric CAROFF and his team have generated impressive preclinical data that will be scaled up towards additional value-creating milestones.” “ELAIA has a proven track record in supporting biotech companies through to the clinic and success, and we are delighted to have them on board” said Frederic CAROFF, CEO and co-founder of HEPHAISTOS-Pharma.

弗雷德里克·卡洛夫（FrédéricCaroff）和他的团队已经产生了令人印象深刻的临床前数据，这些数据将被扩大到创造额外价值的里程碑。”HEPHAISTOS Pharma首席执行官兼联合创始人弗雷德里克·卡洛夫（FredericCaroff）表示：“埃利亚（ELAIA）在支持生物技术公司进入临床并取得成功方面有着良好的业绩记录，我们很高兴他们能加入进来。”

“With xista science ventures, Fondation Fournier-Majoie and Noshaq, our consortium of seed investors brings not only the necessary funds, but also complementary expertis.

“我们的种子投资者财团与xista science ventures、Fournation Fournier Majoie和Noshaq合作，不仅带来了必要的资金，还带来了互补的专业知识。